

HÃ©lÃ¨ne Haguët

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3891184/publications.pdf>

Version: 2024-02-01

14
papers

334
citations

1163117

8
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

604
citing authors

#	ARTICLE	IF	CITATIONS
1	The edoxabanâ€M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12680.	2.3	1
2	Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETPâ€based APC resistance. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 802-812.	1.3	3
3	Clinical performance of the Panbio assay for the detection of SARSâ€CoVâ€2 IgM and IgG in COVIDâ€19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 3277-3281.	5.0	7
4	Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 294-305.	2.3	30
5	Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. <i>Cancers</i> , 2020, 12, 1242.	3.7	9
6	The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 1007.	3.5	16
7	BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?. <i>TH Open</i> , 2018, 02, e68-e88.	1.4	21
8	Impact of functional inorganic nanotubes f-INTs-WS2 on hemolysis, platelet function and coagulation. <i>Nano Convergence</i> , 2018, 5, 31.	12.1	11
9	Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 224-232.	2.1	21
10	Characterization of core/shell Cu/Ag nanopowders synthesized by electrochemistry and assessment of their impact on hemolysis, platelet aggregation, and coagulation on human blood for potential wound dressing use. <i>Journal of Nanoparticle Research</i> , 2017, 19, 1.	1.9	1
11	Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 5-12.	2.4	48
12	Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemiaâ€”Reply. <i>JAMA Oncology</i> , 2016, 2, 829.	7.1	4
13	Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival. <i>JAMA Oncology</i> , 2016, 2, 625.	7.1	158
14	BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis on the Risk of Cardiovascular Events, Major Molecular Response and Overall Survival. <i>Blood</i> , 2015, 126, 2785-2785.	1.4	4